Literature DB >> 1432163

Pretargeted immunoscintigraphy: effect of hapten valency on murine tumor uptake.

D A Goodwin1, C F Meares, M McTigue, W Chaovapong, C I Diamanti, C H Ransone, M J McCall.   

Abstract

A method of radioimmunoscintigraphy using bivalent "Janus" haptens with an apparent enhanced affinity ("avidity") for the antibody is described. Janus with 50 micrograms pretargeted Mab WC3A11 resulted in significantly higher murine tumor concentrations (approximately 7%/g) compared to monovalent haptens (approximately 1.4%/g, p < 0.001), and the same high tumor-to-background ratios (approximately 3/1). Janus was synthesized by coupling two molecules of BABE together with a 1,4 butanedithiol linker. Janus itself was rapidly excreted (T1/2b = 42 min) by the kidneys and did not concentrate in any other organs or tissues. Three-step pretargeted immunoscintigraphy (binder, chaser, tracer) with 111In- or 67Ga-Co(III) Janus produced excellent mouse tumor images in 3 hr with high tumor-to-background ratios. The use of short-lived tracers, such as 99mTc and 68Ga, with a T1/2p of hours to image antibodies that localize slowly over several days in vivo is accessible with this new technology.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1432163

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  11 in total

1.  Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods?

Authors:  David M Goldenberg; Chien-Hsing Chang; Robert M Sharkey; Edmund A Rossi; Habibe Karacay; William McBride; Hans J Hansen; Jean-Francois Chatal; Jacques Barbet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-06       Impact factor: 9.236

2.  Affinity enhancement pretargeting: synthesis and testing of a 99mTc-labeled bivalent MORF.

Authors:  Jiang He; Yi Wang; Shuping Dou; Xinrong Liu; Surong Zhang; Guozheng Liu; Donald Hnatowich
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

Review 3.  Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.

Authors:  Robert M Sharkey; Edmund A Rossi; William J McBride; Chien-Hsing Chang; David M Goldenberg
Journal:  Semin Nucl Med       Date:  2010-05       Impact factor: 4.446

4.  Pretargeted radioimmunotherapy for hematologic and other malignancies.

Authors:  Roland B Walter; Oliver W Press; John M Pagel
Journal:  Cancer Biother Radiopharm       Date:  2010-04       Impact factor: 3.099

5.  An improved method for covalently conjugating morpholino oligomers to antitumor antibodies.

Authors:  Jiang He; Guozheng Liu; Shuping Dou; Suresh Gupta; Mary Rusckowski; Donald Hnatowich
Journal:  Bioconjug Chem       Date:  2007-03-27       Impact factor: 4.774

6.  68Ga chelating bioorthogonal tetrazine polymers for the multistep labeling of cancer biomarkers.

Authors:  Brandon Nichols; Zhengtao Qin; Jun Yang; David R Vera; Neal K Devaraj
Journal:  Chem Commun (Camb)       Date:  2014-03-04       Impact factor: 6.222

Review 7.  A semiempirical model of tumor pretargeting.

Authors:  Guozheng Liu; Donald J Hnatowich
Journal:  Bioconjug Chem       Date:  2008-11-19       Impact factor: 4.774

8.  Cancer Imaging and Therapy with Bispecific Antibody Pretargeting.

Authors:  David M Goldenberg; Jean-Francois Chatal; Jacques Barbet; Otto Boerman; Robert M Sharkey
Journal:  Update Cancer Ther       Date:  2007-03

Review 9.  A pretargeting system for tumor PET imaging and radioimmunotherapy.

Authors:  Françoise Kraeber-Bodéré; Caroline Rousseau; Caroline Bodet-Milin; Eric Frampas; Alain Faivre-Chauvet; Aurore Rauscher; Robert M Sharkey; David M Goldenberg; Jean-François Chatal; Jacques Barbet
Journal:  Front Pharmacol       Date:  2015-03-31       Impact factor: 5.810

Review 10.  Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies.

Authors:  Hidekazu Kawashima
Journal:  ScientificWorldJournal       Date:  2014-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.